Introduction {#S1}
============

Advanced therapy medicinal products (ATMPs) have unique attributes which differentiate them from standard pharmaceuticals and biologics. Indeed, ATMPs have curative potential as they address underlying genetic or cellular mechanisms of disease, which means that they can have a dramatic and long-lasting positive impact on health. They act through multiple mechanisms and on different cellular targets.

ATMPs are often administered just once or a handful of times within a short period. However, as they are typically paid as a one-time treatment, they have a high up-front cost. They are complex products and thus, have also difficult manufacturing processes, often requiring highly specialized manufacturing equipment, processes, and skills. Many cell-based gene therapies, for example CAR-T therapy used to treat some blood cancers, are individually manufactured for each patient: cells are collected from the patient's blood using a process called apheresis, they are modified and expanded in the laboratory, and then re-infused into the patient several hours later. These processes are usually carried out by trained individuals in specialized centers.

Overall, ATMPs can also have a positive impact on patient quality of life, caregivers and on the whole society. In fact, the use of ATMPs decreases hospitalization, avoids continuous drug administration, and reduces nursing. Notably, this approach speeds up the patient productivity, enabling quick return to work with no burden on the society.

Thus, ATMPs appear to have the extraordinary potential to offer durable, life-changing solutions for the society. These highly complex treatments rely on current surgical practice and could not prescind from it, but differ from traditional medicines, both in terms of how they are made/administered and by the type of benefits they may provide.

In particular, the 3.3% of total number of ATMP clinical trials worldwide are in the field of ophthalmology ([@B3]). Globally, it is estimated that there are about 2.2 billion people with vision impairment or blindness and at least 1 billion people with a form of vision impairment that could have been prevented or has yet to be addressed ([@B27]).

ATMPs Approved in Europe {#S2}
========================

Advanced therapy medicinal products can be classified into three main types:

1.  **Gene therapy medicinal products:** consist of a vector or delivery formulation containing genes that lead to a therapeutic, prophylactic, or diagnostic effect. The genetic construct is engineered to express a specific transgene. The 'recombinant' genes are inserted into the body and by using such gene therapy constructs, *in vivo* genetic regulation or genetic modification of somatic cells can be achieved. A recombinant gene is a stretch of DNA that is created in the laboratory, bringing together DNA from different sources ([@B9]).

2.  **Somatic-cell therapy medicinal products:** consist of cells or tissues that have been subjected to substantial manipulation, or that are not intended to be used for the same essential function(s) in the recipient body. They can be used to cure, diagnose, or prevent diseases.

3.  **Tissue-engineered products:** these contain engineered cells or tissues that have been modified so they can be administered with the aim of regenerating, repairing, or replacing human tissue.

In addition, there are ATMPs that consist of one of the first three categories combined with one or more medical devices as an integral part of the product, which are referred to as combined ATMPs ([@B8]).

Up to June 2019, a total of 14 ATMPs have been granted marketing authorization in Europe: seven gene therapies, four cell therapies, and three tissue engineered products. However, four ATMPs have been withdrawn from the market because they did not obtain any reimbursement ([Table 1](#T1){ref-type="table"}; [@B24]; [@B3]).

###### 

ATMPs approved in Europe ([@B3]).

  **Drug name**      **Developer**   **Indication**                                                                                                                                                                   **Approval date (EU)**   **Status**   **Therapy**
  ------------------ --------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------ ------------ -------------
  Chondrocelect^®^   TiGenix         To repair a cartilage defect of the knee                                                                                                                                         October 2009             X 01-2017    CT
  Glybera^®^         uniQure         For lipoprotein lipase deficiency (LPLD)                                                                                                                                         October 2012             X 10-2017    GT
  MACI^®^            Vericel         To repair a cartilage defect of the knee                                                                                                                                         June 2013                X 09-2014    T-B T
  Provenge^®^        Dendreon        To treat advanced prostate cancer in men in whom chemotherapy is not yet clinically indicated                                                                                    September 2013           X 05-2015    CT
  Holoclar^®^        Holostem        In adult patients with moderate-to-severe limbal stem-cell deficiency caused by burns, including chemical burns to the eyes.                                                     February 2015            ✓            T-B T
  Imlygic^®^         Amgen           For regionally or distantly metastatic unresectable melanoma                                                                                                                     December 2015            ✓            GT
  Strimvelis^®^      GSK             Adenosine deaminase (ADA)−deficient severe combined immunodeficiency (SCID)                                                                                                      May 2016                 ✓            GT
  Zalmoxis^®^        MolMed          Add-on treatment for HSCT of adult patients with high-risk haematological malignancies                                                                                           August 2016              ✓            CT
  Spherox^®^         CO.DON          To repair a cartilage defect of the knee                                                                                                                                         July 2017                ✓            T-B T
  Alofisel^®^        TiGenix         To treat complex anal fistulas in adults with Crohn's disease                                                                                                                    March 2018               ✓            CT
  Kymriah^®^         Novartis        Certain types of acute lymphoblastic leukemia in people up to 25 years old and in certain adult patients with large B-cell lymphoma                                              August 2018              ✓            GT
  Yescarta^®^        Gilead          CAR T therapy for adults living with certain types of non-Hodgkin lymphoma who have failed at least 2 other kinds of treatment.                                                  August 2018              ✓            GT
  LUXTURNA^®^        Novartis        To treat an inherited retinal disease, indicated for children and adults with vision loss caused by mutations in both copies of the RPE65 gene and enough viable retinal cells   November 2018            ✓            GT
  Zynteglo^®^        BlueBird Bio    To treat a blood disorder known as beta thalassemia in patients 12 years and older who require regular blood transfusions                                                        June 2019                ✓            GT

GT, gene therapy; CT, cell therapy; T-B T, tissue based therapy; ✓, authorized; X, withdrawn.

Among the 10 approved ATMPs, two focus on eye diseases. More specifically, they have been developed to cure blindness or visual impairment. In 2014, the Committee for Advanced Therapies (CAT) recommended Holoclar^®^, the first ATMP ensuring a specific number of stem cells, for the treatment of moderate and severe Limbal Stem Cell Deficiency (LSCD). In February 2015, Holoclar^®^ received conditional approval by the European Medicines Agency (EMA) for the use in the European Union (EU; [@B7]).

The second was Luxturna^®^, approved in 2018 as the first gene therapy to restore vision in people with rare inherited retinal disease, caused by mutations in the *RPE65* gene. This therapy can be provided to patients with enough residual cells in the retina. Ten years of evidence of its safety were proposed and its use has been studied in patients with ages ranging between 4 and 44 years old.

However, being approved in November 2018, Luxturna^®^ has not enough data available to assess the product's impact. It is still too early for a comparison of outcomes of patients treated with Luxturna^®^ versus traditional therapies, after authorization ([@B14]).

Notably, the comparison of the social impacts of different types of therapies can be done when: (i) adequate time from approval is available to evaluate economic consequences, (ii) significant follow-up of patient outcomes is collected with the approved technique, and (iii) routine treatments are available as comparator of ATMP effects.

For example Strimvelis^®^, approved in 2016, has long term follow-up data, but no comparators for economic analysis are available.

As a consequence, we analyzed the use of the first CLET (Cultured limbal epithelial transplantation: Holoclar^®^) for the treatment of blindness and visual impairment. This product was launched in 2015, therefore, extensive information are available on more than 100 patient outcomes with several years of follow up. In addition, alternative approaches are available as comparators, as described below.

Global Data: Blindness and Visual Impairment {#S3}
============================================

Eye health has profound and wide-spread implications in many aspects of life, health, sustainable development, and economy.

Worldwide, visual impairment leads to a considerable economic burden for both affected and non-affected people. The estimated number of people with sight damage is more than 217 million, of which 47 million have severe damage and 170 million have moderate damage, while the number of people who are blind is estimated to be 36 million ([Table 2](#T2){ref-type="table"}; [@B5]; [@B25]).

###### 

Global data on visual impairment and blindness in 2015 ([@B5]).

            **World population (million)**   **Blind (million)**   **Moderate-to-severe VI (million)**   **Mild VI (million)**
  --------- -------------------------------- --------------------- ------------------------------------- -----------------------
  *TOTAL*   7330                             36                    217                                   188.5
  *MEN*     3700                             15.87                 97.76                                 87.11
  *WOMEN*   3630                             20.14                 118.85                                101.44

VI, visual impairment.

Globally the major causes of visual impairment are uncorrected refractive errors (43%) and cataracts (33%). Other causes are glaucoma (2%); and age-related macular degeneration (AMD), trachoma, diabetic retinopathy, and corneal opacities (1%). Furthermore, a large proportion of cases (18%) have an undetermined cause.

Meanwhile, the main causes of blindness are cataracts (51%), glaucoma (8%), AMD (5%), corneal opacities (4%), uncorrected refractive errors and trachoma (3%), and diabetic retinopathy (1%), while 21% of cases have undetermined causes ([Figure 1](#F1){ref-type="fig"}; [@B17]).

![Causes of global blindness and global moderate-to-severe visual impairment in 2010 ([@B17]).](fbioe-08-00440-g001){#F1}

Socio-Economic Impact of Visual Impairment and Blindness: Examples From European Countries {#S4}
==========================================================================================

Visual impairment and blindness have considerable socio-economic consequences attributable to the following:

1.  ***Direct healthcare costs*** incurred within the healthcare system by the government and/or other payers. These include, for example, general ophthalmic services, hospitalizations, treatment, expenditure associated with injurious falls due to visual impairment and blindness, and rehabilitation.

2.  ***Direct non-healthcare costs*** caused by the illness but not imputable to medical treatment: e.g., home improvements (e.g., ramps, door-opening devices, handlebars and tactile assistance systems), technical assistance such as sticks, guide dogs or computer interface, mobility, home care.

3.  ***Indirect costs*** include the economic impacts of this condition outside the healthcare system and on the wider society. These include:

    1.  *Reduced productivity* of the patients and their caregivers due to absenteeism, limited efficiency at work (presenteeism), part-time employment or loss of work,

    2.  *Informal cares* (family or social care),

    3.  *Social security costs* (invalidity pensions or accompanying allowance, financial support for income, residence, or benefits).

4.  ***Intangible costs*** reflecting the burden of the disease in terms of worsening of the patient's quality of life due to, for example, pain and other aspects such as the stress felt by the caregiver. Indeed, these can be tangible to some extent, such as in cases of costs related to depression, anxiety and further excess of morbidity. These can be traced back to other types of direct healthcare costs that can be easily calculated ([@B11]; [Figure 2](#F2){ref-type="fig"}).

![Schematization of total costs for a blind and visually impaired patient.](fbioe-08-00440-g002){#F2}

Among direct non-healthcare costs, those dedicated to home improvements are not considered in a first analysis, but they have a consistent weight on total costs, as analyzed below.

Home adaptation-costs, reported from Italy, include kitchen and bathroom adjustments such as tactile assistance systems; cost €1,003.30 and €5,994.3, respectively. Similarly, in France, it is reported that the cost for a stair lift for a single patient is €6,000, while in Germany the cost of door-opening devices is €1,900 per unit ([@B13]).

Studies on cost of illness are a pivotal measure in healthcare, to assess the economic burden of a disease on the society. These studies support the quantification of the "hidden" costs of illness and so help to reveal the true disease-related charges. This is important because costs have a key role in public policy making and could help decision makers to prioritize medical costs, including research.

In fact, doing a cost-benefit analysis (CBA), the inclusion of marginal cost in the evaluation is emphasized, as it should not be a "on/off" decision, but rather a "more/less" decision.

An economic calculation may reveal, despite an apparent level of spending, that the additional (marginal) costs can change the final result of the cost evaluation ([@B28]).

Investments on ATMP that could cure patients with visual impairment, will lead to a healthier population, which in turn, could result in a more affordable medical budget for governments, a healthier tax-paying workforce, and lower productivity losses, improving the wellbeing and quality of life of patients and their caregivers.

Here, we analyzed the annual costs of blindness and visual impairment reported in three western countries (from EU) in order to compare direct healthcare costs, direct non-healthcare costs, and indirect costs ([Figure 3](#F3){ref-type="fig"}). Indeed, three studies were proposed by Netherland ([@B22]), United Kingdom ([@B19]), and Germany ([@B6]) for a cost-benefit analysis; this CBA was based on a previously made contingent valuation (CV), used to estimate economic values for all kinds of services. In the selected countries, the global cost for all visual impaired and blind individuals was divided by the number of the total patients in each Country, in the specific year ([@B28]). In particular, results revealed that the direct healthcare costs of blind and visual impaired individuals represented just a small percentage of the total cost of this disability. Instead, the largest percentage of the costs, was due to productivity loss, social security costs, and informal support/care by caregivers. These results highlight the crucial role that indirect costs, usually not considered, play in the total cost of illness.

![In this table and figure are represented the direct healthcare costs, the direct non-healthcare costs and the indirect costs for some European Countries per unit (for each blind and visually impaired patient) ([@B19]; [@B22]; [@B6]). VI, visually impaired. Numerical data for UK have been converted from GBP to Euro.](fbioe-08-00440-g003){#F3}

Economic Benefit of ATMPs Compared to Traditional Therapies: Focus on Treatment of Limbal Stem Cell Deficiency {#S5}
==============================================================================================================

The aim of the treatment for LSCD is to restore the surface of the eye, achieve corneal clarity and improve visual acuity in monolateral or partial bilateral blindness. Current treatment practices usually start with supportive care treatments such as lubrication, autologous serum eye drops, antibiotics, anti-inflammatory drugs, and therapeutic soft or scleral contact lenses. Conservative surgery such as corneal scraping may also be offered before attempting limbal stem cell transplantation. The latter includes several types of invasive surgical options, the aim of which is to transplant stem cells to the affected eye. The surgical options differ in terms of where the cells come from and how they are transferred, specifically the following:

1.  Conjunctival limbal autograft (CLAu), in which stem cells are taken from the contralateral uninjured limbal tissue from the patient's healthy eye.

2.  Conjunctival limbal allograft (CLAL), in which stem cells are taken from a living, related donor or dead donor and transplanted into the diseased eye of the recipient.

3.  Keratolimbal allograft (KLAL), transplants the entire limbus from a dead donor using the corneoscleral carrier to deliver a large number of stem cells to the recipient.

4.  Simple limbal epithelial transplantation (SLET), reduces the tissue withdrawal of CLAu, but it can treat milder severity (superficial lesions) than CLET. In the SLET procedure, re-epithelialization is slower than in some of the other therapies (it takes about 5--6 weeks) ([@B21]; [@B23]).

5.  Cultured limbal epithelial transplantation (CLET) procedure ([@B18]) has some advantages compared to CLAu, for example it starts from a smaller amount of limbal tissue (1--2 mm^2^), minimizing the risk of injury to the healthy eye. In addition, CLET does not require lifelong immunosuppression and in cases of failure, the treatment can be repeated multiple times.

Due to the evidence of its safety and efficacy, one specific CLET technique, under the name Holoclar^®^, has been conditionally approved in 2015 by the EMA as the first stem cell−based therapy ([@B7]).

Some non ATMP-treatments can have disadvantages. For example, CLAu requires a large amount of donor tissue from the healthy eye (equivalent to around 40% of the available donor cornea). This increases the risk of damage to the donor eye and the treatment cannot be repeated in case of failure. The CLAu technique leads complete corneal epithelialization from day 18 up to several weeks after surgery ([@B12]).

In contrast, the use of the approved cultured stem cell therapy (Holoclar^®^) has several advantages, such as the absence of immunological rejection (autologous cells do not require immunosuppression), the use of a small limbal biopsy (1--2 mm^2^), and the standardization of each preparation of the product made individually from the donor's cells for a single treatment. It is important to note that treatments can be repeated multiple times if both eyes need to be cured ([@B7]; [@B15]).

Thus, the cost of each traditional therapy could appear lower than the cost of an advanced therapy (see [Tables 3.1](#T3){ref-type="table"}--[3.3](#T5){ref-type="table"}), however, a more global evaluation of ATMPs leads to a different conclusion. Advanced therapy medicinal products can reduce hospital stay, medical evaluations, additional therapies, nursing costs, and finally, both direct non-healthcare and indirect costs. In fact, cost evaluation regarding cases of vision loss or blindness requires inputs to assist decision makers (e.g., surgeons, patients, payers), to calculate the cost effectiveness of different treatments as a whole and prioritize health expenditure for the society.

###### 

Summarizes an example of costs for different LSCD treatments.

             **LSCD Costs up to Surgery (€)**   
  ---------- ---------------------------------- ------------
  CLAu                                          € 21,893
  Lr-CLAL                                       € 65,479
  KLAL                                          € 77,393
  SLET                                          € 21,000\*
  BSC                                           € 88,377
  Holoclar                                      € 93,907

CLAu, limbal conjunctival autograft; Ir-CLAL, conjunctival limbal allograft tissue from living relatives; KLAL, keratolimbal allograft; BSC, best supportive care, SLET, simple limbal epithelial transplantation. Data have been converted from GBP to Euro from

NICE (2017a)

. \*Data estimated by

Table 2

(

Sangwan et al., 2012

) that consider that SLET has the same cost as CLAu.

###### 

Comparison between therapies -- qualitative analysis.

                                           **CLET**                          
  ---------------------------------------- --------------------------------- ------------------------------------------------------------------
  **Costs to add to each surgery**                                           
  Hospitalization after surgery            1 day                             Variable
  **Drugs/Medications needed**                                               
  Therapeutic contact lens                 Not required                      Yes
  Amniotic membrane                        Not required                      Yes
  Antibiotic eye drops                     \+                                ++
  Steroid eye drops                        \+                                ++
  Artificial tears                         \+                                \+
  Outpatient appointments (first year)     At least 6 appointments           At least 9 appointments
  **Other costs to add to each therapy**                                     
  Home treatment                           Self-medication                   Medications At least 5 weeks up to complete re-epithelialization
  Cost up to complete epithelialization    3--7 days                         5--6 weeks
  Invalidity/productivity loss             Days                              Months
  Pharmacovigilance on adverse event       Yes                               Absent
  Reproducibility of results               Highly standardized GMP setting   Not standardized setting
  Proven inter-hospital consistency        Yes                               No

This Table lists different treatments included in each therapy. The list of drugs and medications was taken from

Basu et al. (2016)

for SLET and

AIFA (2019)

for Holoclar. + used during the therapy, + ⁣ + used in higher amount than the comparator.

###### 

Comparison between therapies -- quantitative analysis.

                                                                 **CLET (Holoclar^®^)**                                        **SLET**
  -------------------------------------------------------------- ------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------
  Up-front cost of therapy                                       € 93,907 (cost of surgery)                                    € 21,000
  **Long-term healthcare costs**                                                                                               
  Long-term stability\*\*                                        23.4% failures up to 10 years (based on a proven follow-up)   24.8% failures up to 4 years (based on a proven 4 years follow-up) + 6 years hypothetical stability (best case) Or 6 years potential 100% failure (worst case)
  Total potential cost of failures ^§^ in 10 years (follow-up)   € 206,802                                                     € 220,943--€ 618,639
  Total potential partial cost including surgery                 € 300,709                                                     € 241,943--€ 639,639

In this table, the percentage of failure has been calculated from

Rama et al. (2010)

for Holoclar

®

and

Basu et al. (2016)

for SLET. \*\*Failure rate and long-term stability were calculated on reported successful outcomes and proven 10 years follow-up for Holoclar

®

(

Rama et al., 2010

), and 4 years follow-up reported for SLET (

Basu et al., 2016

). The following 6 years (required to compare the data with ATMP) of SLET have been considered as a range: from a best case scenario as stable percentage of failure (24.8%) (

Basu et al., 2016

) to the worst case of late failure (100%).

§

The cost of failure was based on expenses for Best Supportive Care (BSC in

Table 3.1

).

Procedure standardization, at the production and clinical application level, implies a clear definition of reproducibility on raw materials, production, clinical protocol, training of surgeons, long-term follow-up, and monitoring of adverse events, as requested by regulatory authorities.

Standardization has an impact on cost evaluation of the procedure. The absence of these guarantees results in highly variable results (potentially 0--100%), unknown long-term efficacy, and absence of pharmacovigilance on adverse events. Altogether, these missing points produce uncontrolled long-term increase/variability of costs (of the procedure) as calculated in [Table 3.3](#T5){ref-type="table"}.

Another advantage of the ATMP is that it uses new autologous healthy tissue grown in the laboratory that can be implanted onto the damaged cornea, healing the receiving eye in a few days with a rapid decrease in the patient's symptoms ([Figure 4](#F4){ref-type="fig"}).

![Data from the first Holoclar clinical trial (HLSTM01) based on 97 patients ([@B15]).](fbioe-08-00440-g004){#F4}

Results in [Figure 4](#F4){ref-type="fig"} could be explained by the minimally invasive surgery required. Patients are usually able to go back home in one or a few days, compared to traditional surgeries requiring longer healing time.

Current clinical practices mainly rely on day surgeries, with a decrease on in-hospital patient average length of stay (days) in EU countries over the past few years, although the pace of diffusion has varied widely across countries.

Indeed, [Figure 5](#F5){ref-type="fig"} shows that hospitalization has been reduced over the past 10 years, highlighting a clear tendency to decrease this cost for the society.

![In-patient average length of hospital stay (days) in different EU countries. This figure shows the number of days a single patient stays in hospital. It shows that the number of days in the hospital decreases with the years. These data refer to "diseases of the eye and adnexa" EUROSTAT category ([@B10]).](fbioe-08-00440-g005){#F5}

Therapies not following this trend, require an extension of the recovery and associated medical evaluations; they create cost-related problems and, above all, organizational problems to the entire healthcare system.

It is worth noting that patients with a less severe condition and an acceptable quality of life are less likely to suffer co-morbidities or adverse events requiring further, potentially expensive, therapies and support. Different studies have showed that visually impaired patients suffer from increased levels of depression, psychological stress, anxiety, and mental fatigue. It is estimated that depression occurs in patients with visual impairment more often (about 17%) than in patients with no vision damage ([@B26]). Thus, depression is an additional cost for the society that could be avoided with timely patient treatment and effective sight recovery. For example, in Netherlands, psychological rehabilitation for each visually impaired patient costs about €432.6 per year ([@B22]). This continuative cost, for both blind or visually impaired patients, for several years is a burden for the society and cannot be ignored.

Conclusion and Future Perspectives {#S6}
==================================

A careful scientific and economic evaluation of the additional costs of each therapy should drive the selection of affordable medical solutions. As the number of ATMPs is increasing, the high prices associated with them have become the topic of many debates. Here, we have focused on sight recovery as it is a critical issue worldwide.

Beyond the value of ATMPs for healthcare and considering the total cost for a single patient, it is important to consider healthcare-related costs as well as non-healthcare and indirect costs to perform an appropriate evaluation. It is necessary to have a holistic view on expenses for the government, especially in the case of therapies with high up-front costs.

Hospitalization, home care, medical evaluations and adverse events are the most relevant costs for a blind or visual impaired patient. However, costs are not only related to the length of stay in hospital, but also to the hospital's logistic expenses, to the cost of physicians and nurses that take care of patients for months and to other expenditures. Such costs are widely reduced with the new innovative therapies.

Nevertheless, it is also important to consider the global experience of the patient and the possible correlated illnesses such as infections, pain and depression caused by prolonged and non-resolutive therapies. Patients often undergo long-term treatments with drugs in order to reduce symptoms but without any sight restoration. They live with pain and related depression and are not productive, representing often a burden for the society ([@B16]).

Supportive care or surgical approaches can appear, at first, as cheaper choices but, afterward, they are often less effective than new therapies. These last ones potentially bring more significant benefits, especially in the long-term, not only for the success of the treatment but also for the caretakers, families, and for the society as a whole.

Therefore, the main aim of each therapy and treatment is patient's healthcare, its satisfaction and self-sufficiency, all in the frame of economic sustainability.

Finally, the costs of ATMPs include GMP production costs. The apparently high up-front costs of ATMPs are compensated by the high levels of therapy standardization and safety, ensuring a cost/benefit ratio. Concerning R&D, its related costs are compensated by the usefulness of R&D in assessing public policies and stimulating drug development and innovation.

Overall, our analysis highlights that, globally, there is not increase in the costs of ATMPs versus surgery, due to their guarantee of success and short duration.
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